GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance

U.S. Markets closed

Gilead Sciences Inc. (GILD)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
69.29-0.56 (-0.80%)
At close: 4:00PM EST

69.25 -0.04 (-0.06%)
After hours: 7:59PM EST

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close69.85
Bid69.25 x 400
Ask69.29 x 100
Day's Range68.83 - 70.00
52 Week Range65.38 - 103.10
Avg. Volume10,727,665
Market Cap90.77B
PE Ratio (TTM)6.97
Earnings DateN/A
Dividend & Yield2.08 (2.98%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal59 minutes ago

    [$$] Gilead Goes to the Head of the Line

    Gilead Sciences’s approach to the biotech deals market involves more than just waiting.

  • American City Business Journals7 hours ago

    Did Gilead's new tool for speeding drug approval come at bargain-basement price?

    Gilead Sciences Inc. spent $125 million for a voucher that could speed FDA review of a drug, but one analyst said the seller may have undervalued the asset. Sarepta Therapeutics of Cambridge, Mass., on Tuesday said it sold the so-called priority review voucher to Foster City-based Gilead Sciences Inc. (GILD). Sarepta (SRPT) had received the rare pediatric disease voucher when the Food and Drug Administration approved its Duchenne muscular dystrophy drug, Exondys51, in September.

  • Investopedia10 hours ago

    Sarepta Sells Priority Review Voucher for $125M

    Sarepta sold its Priority Review Voucher for $125 million to Gilead.